LONDON, UK / ACCESSWIRE / April 13, 2023 / Nanomerics Ltd., a private speciality pharmaceutical company today announced that the Company had been granted patent protection in Canada for the ocular use of its Molecular Envelope Technology (MET) drug delivery system. The patent (CA2966592), granted by the Canadian Intellectual Property Office joins other similar patents granted in multiple territories and takes Nanomerics' patent protection of its ocular franchise, in Canada, to 2035. Nanomerics' MET enables the efficient delivery of drugs to the front and back of the eye using transparent and oil-free eye drops. Nanomerics' MET is a non-irritant delivery system for hydrophobic and polyanionic drugs and, crucially, the technology is also an ocular penetration enhancer. The technology delivers up to 18 fold higher drug levels to the ocular surface tissues when compared to eye drop suspensions, with no detectable plasma exposure. This allows a lower drug concentration to be used in Nanomerics' eye drops and provides an additional safety benefit. In preclinical rabbit models, Nanomerics' MET also enables the delivery of therapeutic levels of active pharmaceutical ingredients to the retina, using eye drops. Nanomerics' MET has been used to formulate eye drops such as: OC134, indicated for severe allergic eye disease and OC137, indicated for the treatment of retinal diseases. Nanomerics is currently executing an OC134 Phase I clinical trial project. The conclusion of trial will transform the company to a clinical stage company and enable Nanomerics' MET to be used for a variety of ophthalmic active pharmaceutical ingredients. Positive results from this clinical study will allow the company to fully exploit Nanomerics' MET and deliver the potential benefits of this technology to patients with ocular conditions. Nanomerics has a pipeline of ophthalmic medicine candidates. Nanomerics' MET also underpins a number of Nanomerics' central nervous system assets. Noteworthy among these is Envelta™, a nasal spray powder, which is being developed as a pain therapeutic. Envelta™ has been out-licensed by Nanomerics to Virpax Pharmaceuticals (NASDAQ:VRPX). Envelta™ is being developed by Virpax Pharmaceuticals in collaboration with the US National Institutes of Health (NIH). Nanomerics also has other collaborations with companies aiming to develop central nervous system assets using its MET. Nanomerics is based in state of the art laboratories in North London. Nanomerics' Chief Scientific Officer, Professor Ijeoma F. Uchegbu, says, "we are delighted with the granting of this patent in a key commercial territory and look forward to generating clinical results for the benefit of ophthalmology patients." About Nanomerics Nanomerics Ltd is a speciality pharmaceutical company based in London, UK. Nanomerics was founded to commercialise its biocompatible polymer technologies for drug delivery and other applications. Nanomerics' proprietary technology is based on world leading know-how and scientific leadership in polymer nanotechnology. Nanomerics creates uniquely differentiated, patented pharmaceutical assets, underpinned by high quality science. For example, the company's Molecular Envelope Technology (MET) is a unique patented biocompatible polymer that delivers a step change in target tissue bioavailability. The founding scientists, Professor Ijeoma F. Uchegbu and Professor Andreas G. Schätzlein developed the technology at the Universities of Strathclyde and Glasgow and, latterly at the UCL School of Pharmacy. Pharmaceutical product candidates in development include the eye drops: OC134 for the treatment of moderate to severe allergic conjunctivitis and OC137 for the treatment of retinal diseases. Additionally, a number of pharmaceutical product candidates have already been out-licensed by Nanomerics to Virpax Pharmaceuticals (NASDAQ: VRPX), e.g. Envelta™, which is being developed as a pain therapeutic, AnQlar™, being developed as an anti-viral nasal spray and NobrXiol™, in development for the treatment of epilepsy. For more information please visit Forward-Looking Statements This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Nanomerics cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. Forward-looking statements reflect our analysis only on their stated date, and Nanomerics takes no obligation to update or revise these statements except as may be required by law. Contact: Name: Pedro Margarido Company: Nanomerics ltd Email: businessdevelopment@nanomerics.com Contact: +44 2045585366 SOURCE: Nanomerics Ltd View source version on accesswire.com:

临床1期

2022-08-31

·BioSpace

Nanomerics Awarded an MHRA Innovation Passport for OC134

LONDON, UK / ACCESSWIRE / August 31, 2022 / Nanomerics Ltd., a private speciality pharmaceutical company, today announced that the Company had received an Innovation Passport from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for its lead asset - OC134. The Innovation Passport is the entry point to the Innovative Licensing and Access Pathway (ILAP), which aims to accelerate time to market, facilitating patient access to innovative technologies. Nanomerics is currently engaging with the ILAP in order to fast-track OC134 towards approval by the MHRA. Nanomerics' Sunlight Trial will examine the safety and tolerability of OC134 in human volunteers in 2022. OC134 is indicated for the treatment of severe allergic conjunctivitis. OC134 is enabled by Nanomerics' Molecular Envelope Technology (MET). Nanomerics' MET is non-irritant in relevant animal models and a topical ocular penetration enhancer for the delivery of poorly water-soluble drugs. The technology enables the absorption of 5 - 18 fold more drug into the ocular tissues, on topical administration, when compared to leading commercial formulations. Most of Nanomerics' MET topical ocular formulations do not lead to plasma exposure and thus Nanomerics' MET efficiently targets drug to the ocular tissues. Nanomerics has a pipeline of topical ocular products, which includes OC132 for the treatment of post-operative ocular pain, OC137 for the treatment of non-infectious posterior uveitis and both OC135 and OC136 for the treatment of ocular fungal infections. Nanomerics is using its Molecular Envelope Technology to create formulations that address areas of unmet medical need. Increased drug deposition will enable lower doses to be used, could lead to improved response rates and reduced side effects; effectively improving the therapeutic index of eye drops. Nanomerics' Chief Executive Officer, Professor Andreas G. Schätzlein, says, "we are very pleased that the UK regulator - the MHRA - reacted positively to our application for an Innovation Passport and we look forward to bringing our various ophthalmology assets to patients in a timely manner." About Nanomerics Nanomerics Ltd is a speciality pharmaceutical company based in London, UK. Nanomerics was spun out of University College London, a top 10 global university and was founded to commercialise its biocompatible polymer technologies for drug delivery and other applications. Nanomerics' proprietary technology is based on world leading know-how and scientific leadership in polymer nanotechnology. Nanomerics creates uniquely differentiated, patented pharmaceutical assets, underpinned by high quality science. For example, the company's Molecular Envelope Technology (MET) is a unique patented biocompatible polymer that delivers a step change in target tissue bioavailability. The founding scientists Professor Ijeoma F. Uchegbu and Professor Andreas G. Schätzlein developed the technology at the Universities of Strathclyde and Glasgow and, latterly at the UCL School of Pharmacy. Pharmaceutical product candidates in development include OC134 for the treatment of allergic conjunctivitis and OC137 for the treatment of non-infectious posterior uveitis. Additionally, a number of pharmaceutical product candidates have already been out-licensed by Nanomerics to Virpax Pharmaceuticals (NASDAQ:VRPX), e.g. Envelta™, which is being developed as a pain therapeutic and AnQlar™, which is being developed as an anti-viral nasal spray. For more information, please visit or contact Nanomerics investor relations at info@nanomerics.com. Forward-Looking Statements This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Nanomerics cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. Forward-looking statements reflect our analysis only on their stated date, and Nanomerics takes no obligation to update or revise these statements except as may be required by law. SOURCE: Nanomerics Ltd. View source version on accesswire.com:

2022-07-20

·BioSpace

Nanomerics CSO Made Honorary Fellow of the Royal Society of Chemistry

LONDON, UK / ACCESSWIRE / July 20, 2022 / Nanomerics Ltd., a private speciality pharmaceutical company, today announced that the company's Chief Scientific Officer, Professor Ijeoma F. Uchegbu, had been made an Honorary Fellowship of the UK's Royal Society of Chemistry. The Royal Society of Chemistry is the UK's leading learned society focusing on the chemical sciences. The Honorary Fellowships are the highest awards made by the society and fellowships are awarded for outstanding contributions to the chemical sciences. The fellowship citation referenced Nanomerics' Molecular Envelope Technology and its impact on drug development. The fellowship was presented to Professor Uchegbu at the President's Summer Party at the Royal Academy in London. Professor Uchegbu said, "I am truly honoured to receive this recognition for our scientific achievements including for the invention of our Molecular Envelope Technology; a team effort for which I am thankful to the all the researchers that have worked with us over the years." Nanomerics is currently conducting its first clinical trial on its Molecular Envelope Technology (MET). OC134 is enabled by Nanomerics' MET and the Sunlight Trial will examine the safety and tolerability of OC134 in human volunteers in 2022. OC134 is indicated for the treatment of severe allergic conjunctivitis. Nanomerics' MET is non-irritant in relevant animal models and a topical ocular penetration enhancer for the delivery of poorly water-soluble drugs. The technology enables the absorption of 5 - 18 fold more drug into the ocular tissues, on topical administration, when compared to leading commercial formulations. Most of Nanomerics' MET topical ocular formulations do not lead to plasma exposure and thus Nanomerics' MET efficiently targets drug to the ocular tissues. Nanomerics has a pipeline of topical ocular products, which includes OC132 for the treatment of post-operative ocular pain, OC137, an eye drop formulation, for the treatment of non-infectious posterior uveitis and both OC135 and OC136 for the treatment of ocular fungal infections. Nanomerics is using its Molecular Envelope Technology to create formulations that address areas of unmet medical need. Increased drug deposition will enable lower doses to be used, could lead to improved response rates and reduced side effects; effectively improving the therapeutic index of eye drops. About Nanomerics Nanomerics Ltd is a speciality pharmaceutical company based in London, UK. Nanomerics was founded to commercialise its biocompatible polymer technologies for drug delivery and other applications. Nanomerics' proprietary technology is based on world leading know-how and scientific leadership in polymer nanotechnology. Nanomerics creates uniquely differentiated, patented pharmaceutical assets, underpinned by high quality science. For example, the company's Molecular Envelope Technology (MET) is a unique patented biocompatible polymer that delivers a step change in target tissue bioavailability. The founding scientists Professor Ijeoma F. Uchegbu and Professor Andreas G. Schätzlein developed the technology at the Universities of Strathclyde and Glasgow and, latterly at the UCL School of Pharmacy. Pharmaceutical product candidates in development include OC134 for the treatment of allergic conjunctivitis and OC137 for the treatment of non-infectious posterior uveitis. Additionally, a number of pharmaceutical product candidates have already been out-licensed by Nanomerics to Virpax Pharmaceuticals (NASDAQ:VRPX), e.g. Envelta™, which is being developed as a pain therapeutic and AnQlar™, which is being developed as an anti-viral nasal spray. For more information, please visit or contact Nanomerics investor relations at info@nanomerics.com. Forward-Looking Statements This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Nanomerics cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. Forward-looking statements reflect our analysis only on their stated date, and Nanomerics takes no obligation to update or revise these statements except as may be required by law. SOURCE: Nanomerics Ltd. View source version on accesswire.com:

100 项与 OC137 相关的药物交易

登录后查看更多信息